Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

BioMarin files NDA for Kuvan for PKU

May 25, 2007

Japanese approval for Glufast in combination with alpha-GI

May 25, 2007

Results from phase III trauma trial with PolyHeme

May 25, 2007

Tolerability and activity of MK-0822 on bone resorption markers in healthy postmenopausal women

May 25, 2007

NEJM article suggests rosiglitazone increases risk of heart attack

May 24, 2007

Contrave begins second phase III study for obesity

May 24, 2007

Novel therapeutic agents for obesity described in recent patents

May 24, 2007

Lybrel receives FDA approval

May 23, 2007

KineMed evaluates mechanism of action of colesevelam in type 2 diabetes

May 23, 2007

FDA awards orphan drug status to Ardana's oral growth hormone secretagogue

May 23, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...